DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised

DexCom (DXCM) reported strong third-quarter 2025 results, with adjusted EPS of 61 cents and total revenues of $1.21 billion both exceeding analyst estimates, representing 7% and 2.7% beats respectively, driven by 21.6% year-over-year revenue growth. The company also raised its 2025 revenue guidance to $4.63-$4.65 billion, citing continued strong demand and expanding access for continuous glucose monitoring (CGM), particularly in the type 2 diabetes market. Despite these positive financial and outlook updates, DXCM shares fell nearly 12.8% in after-hours trading, with adjusted gross margin experiencing a 160 basis point year-over-year decline to 61.3% due to temporary manufacturing scrap rates, which management expects to normalize.

Analysis

DexCom (DXCM) reported robust third-quarter 2025 results, with adjusted EPS of $0.61 exceeding the Zacks Consensus Estimate by 7% and total revenues of $1.21 billion surpassing expectations by 2.7%. Revenue growth was strong at 21.6% year-over-year (20% organic), driven by increased demand and expanding access for continuous glucose monitoring (CGM), particularly in the type 2 diabetes segment. Sensor and other revenues, comprising 97% of the total, grew 23% to $1.18 billion, while U.S. revenues increased 21% to $851.9 million.

The company raised its 2025 revenue guidance to $4.63-$4.65 billion, implying 15% year-over-year growth, reflecting confidence in its market expansion strategies. Key initiatives include the broader rollout of the 15-day G7 sensor, international growth in markets like France and Canada, and the scaling of Stelo, which generated over $100 million in its first year. DexCom anticipates unlocking a significant addressable market of over 25 million Americans through PBM coverage expansion for non-insulin type-2 users.

Despite these positive financial and strategic updates, DXCM shares declined almost 12.8% in after-hours trading, contributing to a 12.3% year-to-date loss. This market reaction likely stems from the 160 basis point year-over-year decrease in adjusted gross margin to 61.3%, attributed to temporary higher scrap rates, even though management expects recovery. The current Zacks Rank #4 (Sell) further reflects a cautious outlook despite strong operational performance.

Key Decisions for Investors

• Investors should closely monitor DexCom's adjusted gross margin recovery in upcoming quarters, as the Q3 decline due to scrap rates appears to be a primary driver of the negative market reaction despite strong top-line growth and raised guidance.
• Evaluate the sustainability of DXCM's market expansion, particularly in the non-insulin type 2 diabetes segment and international markets, against potential competitive pressures and the company's ability to maintain pricing power.
• Consider the implications of the Zacks Rank #4 (Sell) in conjunction with the company's robust operational performance and strategic initiatives, assessing if the current valuation adequately reflects both growth prospects and margin-related risks.